1 Name of the Medicinal Product
Shan6®, suspension for injection in vial presentation.

Diphtheria, Tetanus, Pertussis (Whole Cell), Hepatitis B (rDNA), Haemophilus influenzae Type b Conjugate and Poliomyelitis (Inactivated) Vaccine (Adsorbed).

2 Qualitative and Quantitative Composition

<table>
<thead>
<tr>
<th>Name of active substance</th>
<th>Quantity per 0.5 mL single dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diphtheria Toxoid</td>
<td>≥30 IU¹</td>
</tr>
<tr>
<td>Tetanus Toxoid</td>
<td>≥60 IU¹</td>
</tr>
<tr>
<td>Bordetella pertussis (Whole Cell inactivated)</td>
<td>≥4 IU</td>
</tr>
<tr>
<td>rDNA Hepatitis B Surface Antigen</td>
<td>10 µg²</td>
</tr>
<tr>
<td>Haemophilus influenzae type b polysaccharide (Polyribosyl Ribitol Phosphate) conjugated to tetanus toxoid 22 to 40 µg</td>
<td>12 µg³</td>
</tr>
<tr>
<td>Poliomyelitis virus (Inactivated) Type 1 (Mahoney Strain)¹</td>
<td>29 DU”</td>
</tr>
<tr>
<td>Type 2 (MEF-1 Strain)²</td>
<td>7 DU”</td>
</tr>
<tr>
<td>Type 3 (Saukett Strain)³</td>
<td>26 DU”</td>
</tr>
</tbody>
</table>

¹The lower confidence limit (P = 0.95)
²Produced in yeast Hansenula polymorpha cells by recombinant DNA technology
³Expressed as amount of polysaccharide
⁴Produced on VERO cells
⁵DU: D Antigen Unit

The vaccine may contain traces of neomycin, streptomycin, polymyxin B, and essential amino acids including L-Phenylalanine.

For the full list of excipients, see Section 6.1

3 Pharmaceutical form
Suspension for injection in multi-dose vials. Shan6 is a whitish turbid suspension in which the Aluminium Phosphate adjuvant tends to settle down slowly on storage.

4 Clinical Particulars

4.1 Therapeutic Indications
Shan6 is indicated for primary vaccination against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive diseases caused by Haemophilus influenzae type b from the age of 6 weeks onwards, in accordance with official recommendations.

4.2 Posology and Method of administration

Posology

Primary vaccination:
The primary vaccination schedule consists of 3 doses of Shan6 injection (0.5 mL each) to be administered intramuscularly at an interval of at least 4 weeks in accordance with official recommendations.

Shan6 can be used whether or not a dose of Hepatitis B vaccine has been given at birth.
Method of Administration

Shan6 must be administered intramuscularly only. The recommended injection site is generally the anterolateral aspect of the upper thigh in infants and toddlers. Do not administer via intravascular route: ensure that the needle does not penetrate a blood vessel. Separate syringes, separate injection sites, and preferably separate limbs must be used in case of concomitant administration with other vaccines.

4.3 Contraindications

- History of severe allergic reaction to any component of the vaccine or to any pertussis vaccine, after previous administration of the vaccine or a vaccine containing the same components or constituents.
- History of encephalopathy within 7 days of administration of a previous dose of any vaccine containing pertussis antigens (whole cell or acellular pertussis vaccines).
- History of progressive neurologic disorder, uncontrolled epilepsy, or progressive encephalopathy. Pertussis vaccines should not be administered to individuals with these conditions until the treatment regimen has been established, the condition has stabilized, and the benefit estimated to clearly outweigh the risk.

4.4 Special Warnings and precautions for use

Hypersensitivity

Caution should be exercised when Shan6 is administered to subjects with hypersensitivity to formaldehyde, neomycin, streptomycin and polymyxin B.

Protection

- Shan6 will not protect against hepatitis infection caused by other agents such as hepatitis A, hepatitis C, and hepatitis E viruses or by other liver pathogens.
- Because of the long incubation period of hepatitis B virus infection, it is possible for unrecognized hepatitis B infections to be present at the time of vaccination. The vaccine will not prevent hepatitis B infection in such cases.
- Shan6 does not protect against infectious diseases caused by other serotypes of Haemophilus influenzae or against meningitis of other origins.
- As with any vaccine, vaccination with Shan6 may not protect 100% of susceptible individuals against the target diseases.

Special patient groups

- The immunogenicity of the vaccine may be reduced by immunosuppressive treatments or immunodeficiency conditions. It is recommended to postpone vaccination until the end of such treatment or diseases. Nevertheless, vaccination of subjects with chronic immunodeficiency, such as untreated HIV infection, is recommended even if antibody responses to some vaccine antigens may be limited.
- No data are available for premature infants with Shan6. Lower immune response may be observed in this population in relation with immaturity of the immune system. However, according to several national recommendations, vaccination should not be delayed.
• The potential risk of apnea and the need for cardio-respiratory monitoring for 48 to 72 hours should be considered when administering the primary immunization series to very premature infants (born ≤28 weeks of gestation) and particularly for those with a previous history of respiratory immaturity. As the benefit of vaccination is high in this group of infants, vaccination should not be withheld or delayed.

• In chronic renal failure subjects, impaired hepatitis B vaccine response has been observed and administration of additional doses of hepatitis B vaccines should be considered according to the antibody level against hepatitis B virus surface antigen (anti-HBsAg).

• If Guillain-Barre syndrome has occurred following the receipt of prior vaccine containing tetanus toxoid, the decision to give any vaccine containing tetanus toxoid should be based on careful consideration of the potential benefits and possible risks, such as whether or not the primary immunization schedule has been completed. Official recommendations should be followed to assess whether vaccination is justified in such circumstances.

Precautions

• Do not administer by intravascular injection.

• Vaccination should be postponed in children suffering from moderate-to-severe acute febrile illness or infection and until resolution. The presence of a minor infection and/or low-grade fever should not result in the deferral of vaccination.

• As with all injectable vaccines, the vaccine must be administered with caution to subjects with thrombocytopenia or a bleeding disorder because bleeding may occur following an intramuscular administration.

• As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine.

• If any of the following events are known to have occurred in temporal relation to receipt of one pertussis-containing vaccine, the decision to give further doses of one pertussis-containing vaccine should be carefully considered:
  o Temperature of ≥40°C within 48 hours not due to another identifiable cause
  o Collapse or shock-like state (HHE) within 48 hours of vaccination.
  o Persistent, inconsolable crying lasting ≥3 hours, occurring within 48 hours of vaccination.
  o Convulsions with or without fever, occurring within 3 days of vaccination.

4.5 Interaction with other medicinal products and other forms of interaction

Diphtheria, Tetanus, Pertussis (Whole Cell), Hepatitis B (rDNA), *Haemophilus influenzae* Type b Conjugate and Poliomyelitis (Inactivated) vaccines are expected not to interfere with OPV, Measles vaccine, Measles Mumps and Rubella (MMR) vaccine and Oral Rotavirus Vaccine (ORV).

Data on concomitant administration of Shan6 with ORVs have shown no clinically relevant interferences on the antibody responses to each of the individual vaccine antigens when given as a 3-dose primary vaccination.

Except in the case of immunosuppressive therapy (See Section 4.4), no significant clinical interaction with other treatments or biological products has been reported.
4.6 Pregnancy and Lactation
Shan6 is intended for use in pediatric populations.

4.7 Effect on ability to drive and use machines
Not applicable.

4.8 Undesirable effects
The following CIOMS frequency rating is used.

- **Very common**: ≥10%
- **Common**: ≥ 1 and < 10%
- **Uncommon**: ≥ 0.1 and < 1%
- **Rare**: ≥ 0.01 and < 0.1%
- **Very rare**: < 0.01%
- **Not known**: cannot be estimated from available data

*Adverse event information is derived from clinical trials with Shan6.*

The safety of Shan6 was assessed in two randomized, controlled clinical trials in which 1059 infants aged 6 to 8 weeks, 10 to 12 weeks, and 14 to 16 weeks received 3 doses (0.5-mL) of Shan6 in primary series. For all subjects, safety evaluations were performed during the first 28 days following each vaccination.

Most of reactions usually occurred within the first 3 days following vaccination and resolved spontaneously within 1 to 3 days after onset. The intensity of these reactions was mild to moderate. In the primary series, reactions were observed to be more frequent after the first dose and less frequent after the subsequent doses.

**Primary series (3 doses with 4 weeks apart) involving 1059 Infants (starting at 6 weeks of age).**

Very commonly observed reactions were injection-site pain, injection-site erythema, injection-site swelling, pyrexia, vomiting, crying, somnolence, decreased appetite, and irritability. The reactions were observed to be more frequent after the first dose and less frequent after the subsequent doses.

**Uncommon**: Injection-site nodule, Injection site induration

**Potential Adverse Events**

(i.e., adverse events that have been reported with other vaccines containing one or more of the components or constituents of Shan6 and not directly with Shan6).

- Encephalopathy/encephalitis
- Hypotonic Hyporesponsive Episodes
- Convulsions
- Extensive limb swelling: Large injection site reactions (>50 mm), including extensive limb swelling from the injection site beyond one or both joints, have been reported in children. These reactions start within 24 to 72 hours after vaccination; may be associated with erythema, warmth, tenderness, or pain at the injection site; and resolve spontaneously within 3 to 5 days. The risk
appears to be dependent on the number of prior doses, with a greater risk following the 4th and 5th doses.

- Oedematous reaction affecting one or both lower limbs may occur following vaccination with *Haemophilus influenzae* type b containing vaccines. If this reaction occurs, it is mainly after primary injections and within the first few hours following vaccination. Associated symptoms may include cyanosis, redness, transient purpura, and severe crying. All events should resolve spontaneously without sequel within 24 hours.

4.9 Overdose
Not documented.

5 Pharmacological properties

5.1 Pharmacodynamic properties
Pharmaco-therapeutic group: Bacterial and viral vaccines combined, ATC code J07CA09

*Immunogenicity*
In pivotal Phase III study (SH600003), the seroprotection rates 28 days after primary vaccination (3 doses) were at 100% for diphtheria, tetanus, *Haemophilus influenzae* type b, types 1 and type 3 of polioviruses and at 99.7% for hepatitis B and type 2 of poliovirus. For pertussis, the vaccine response rates were at 84.3% for anti-pertussis toxin (PT), 97.7% for anti-fimbriae (FIM), 75% for anti-filamentous hemagglutinin (FHA) and 85.1% for anti-pertactin (PRN) antibodies.

5.2 Pharmacokinetic properties
Not applicable.

5.3 Pre-clinical Safety data
Nonclinical data revealed no special hazard for humans based on single-dose and repeat-dose toxicity studies and local tolerance studies.

6 Pharmaceutical Particulars

6.1 List of Excipients

<table>
<thead>
<tr>
<th>Name</th>
<th>Quantity per 0.5-mL single dose(^\text{A})</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aluminium Phosphate Gel equivalent to Al(^{+++})</td>
<td>0.625 mg</td>
</tr>
<tr>
<td>Sodium Chloride I.P.</td>
<td>4.5 mg</td>
</tr>
<tr>
<td>Water for Injections I.P.</td>
<td>q.s. to 0.5 mL</td>
</tr>
</tbody>
</table>

\(^\text{A}\) Multi-dose vial contains preservatives: 2-phenoxyethanol\(^b\) (0.6% v/v) and formaldehyde (6.25 µg)

\(^b\)2-phenoxyethanol contained in a solution of 2-phenoxyethanol at 50% in ethanol
Sodium hydroxide and Acetic acid (glacial) are used for pH adjustment.

6.2 Incompatibilities
Shan6 must not be mixed with other vaccines or other parenterally administered drugs.
6.3 Shelf-Life
The shelf life is 30 months.

6.4 Special precautions for storage and handling
Store in a refrigerator (+2°C to +8°C). Do not freeze. Discard vaccine if frozen. Vaccine should be protected from light.
Before use, the vaccine should be shaken in order to obtain a homogeneous whitish turbid suspension.
For a multi-dose vial, after first opening, the vaccine can be used for up to 28 days, provided it is stored between +2°C to +8°C.
Do not use this vaccine after the expiry date which is stated on the carton and the label.
The suspension should be visually inspected prior to administration. In the event of any foreign particulate matter and/or variation of physical aspect being observed, discard the vial.

6.5 Nature and content of container
5.0 mL ten dose vial (USP type I glass) with grey bromo butyl rubber stopper and Aluminium flip-off seal.

6.6 Special precautions for disposal
After use, any remaining vaccine and container must be disposed of safely, preferably by heat inactivation or incineration, according to locally agreed procedures.

7 Marketing authorization holder
Sanofi Healthcare India Private Limited
Survey No. 274, Athvelli Village,
Medchal Mandal-501 401,
Medchal -Malkajgiri District, Telangana, India

8 Marketing Authorization Number
MF/BIO/21/000044

9 Date of first authorization/Renewal of Authorization
12/05/2021

10 Date of Revision of the text
22/02/2022.